Shree Ganesh Remedies share price today

Shree Ganesh Remedies Ltd's share price was ₹652.20 at the close on 4 November 2026. It has been rising for 22 weeks. That is 8.2% above its average price over the last 200 trading days. In the last 52 weeks it traded between ₹423 and ₹710, and at that close it sat 80% of the way up from that low.

A share price tends to move through four phases: moving sideways (stage 1), rising (stage 2), stalling near a high (stage 3) and falling (stage 4). Today Shree Ganesh Remedies Ltd is in stage 2. The phase helps read everything below.

Over the past 13 weeks it has done better than the NIFTY 500, and it has stayed ahead for 24 weeks in a row.

Over the last 9.1 years the share price moved +2,564% while the NIFTY 500 moved +144%, so it is ahead of the index over that whole period. The chart above shows the 13-week comparison for every week.

This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row.

Two changes stood out: lowest operating margin in 19 quarters and profit down on a year earlier for 7 quarters in a row.

1. Lowest operating margin in 19 quarters

   Operating margin was 16.9% in the September 2026 quarter, against 31.7% a year earlier.

2. Profit down on a year earlier for 7 quarters in a row

   In the September 2026 quarter profit was ₹2 crore, -67.1% on a year earlier.

For July to September 2026 (the quarter ended 30 September 2026), Shree Ganesh Remedies reported revenue of ₹23.3 crore, down 23.2% from ₹30.3 crore a year earlier, and a profit of ₹1.63 crore, down 67.1% from ₹4.96 crore.

Shree Ganesh Remedies results: July to September 2026 against a year earlier

The next results, for October to December 2026, are due by 14 February 2027: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter).

The newest call in our records is from 15 May 2026, about January to March 2026; a call about these results is not in our records yet.

From the company's reported quarterly results (quarter ended 30 September 2026). Revenue and profit in ₹ crore.

Shree Ganesh Remedies closed at ₹652.20 on 4 November 2026, up 33.3% from ₹489.10 a year earlier (7 November 2025) and up 75.7% over five years. Its highest weekly close since October 2017 was ₹884.30 on 26 July 2024.

Shree Ganesh Remedies share price: then and now

Weekly closing prices. Each change is the move from that price to the 4 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes.

447 weekly closes from 13 October 2017 to 4 November 2026.

4 Nov 2026: Shree Ganesh Remedies closed at ₹652.20, up 5.7% on the week and down 5.9% on the month. Results for July to September 2026: Revenue down 23.2% and profit down 67.1% on a year earlier.

Earlier

• 15 May 2026: Shree Ganesh Remedies held its results call for January to March 2026. Management guided: Block 7 commercial production commencement July to September 2026.

Shree Ganesh Remedies has paid no dividend on the NSE since 1 April 2021, the start of the period we checked.

Not in its latest year. Shree Ganesh Remedies Ltd paid out 0% of its profit as dividends in FY26. It did pay a dividend in 7 of its last 13 reported years, so there is a history but no current dividend.

From the NSE corporate-actions record, read 5 November 2026.

On the call for January to March 2026, held on 15 May 2026, Shree Ganesh Remedies' management guided: Block 7 commercial production commencement July to September 2026.

“We firmly believe it is the right path for the company. It is the path that will allow us to create a more sustainable and more profitable business over the long term, rather than chasing growth in commoditized segments where realizations are under structural pressure”Parth Kotia, Whole-time Director and CFO, on the call for January to March 2026

What management guided

• CRAMS commercial trials expected to commence in latter half FY27 with commercial production thereafter.
• No material CRAMS revenue impact in FY27; approval-stage progress anticipated.
• CRAMS business expected to gain visible traction through FY27 and material ramp-up from FY28 onwards.
• Sustainable long-term operating margin in 26-28% range; initial CRAMS project contributions at elevated levels before normalizing.

Management’s own plans and goals, from our notes of the call. A plan is not a result.

Source: the call transcript.

From the call for January to March 2026, 15 May 2026. The July to September 2026 results are out since, so this part may be out of date until we update it.

When Shree Ganesh Remedies reports October to December 2026, these are the 4 checks that show whether the story is still on course. First: Block 7 commercial production commencement expected July to September 2026 per management guidance; track whether on track end-Q1 or experiences delays into Q3. First new capacity specifically designed for CRAMS projects represents critical path item for strategy.

Shree Ganesh Remedies is not on any of our India lists this week.

Shree Ganesh Remedies Ltd earned ₹1.6 Cr of net profit in the Sep 2026 quarter, −67.1% on the same quarter a year earlier. Full-year FY26 profit was ₹18.0 Cr. Over 10 years profit has grown 33.5% a year on average. That is 7.0% of the quarter's revenue. The same quarter a year earlier earned ₹5.0 Cr.

Net profit is what is left after every cost, interest and tax. Earnings per share, dividends and book value all grow from it.

For the full year, FY26 profit was ₹18.0 Cr (−21.7% on the year before).

Why profit moved: revenue changed −23.2% on a year earlier and the margin moved −14.8 percentage points. Sales did the work while the margin got thinner.

On average over the last four quarters, profit changed −45.6% and revenue −12.8%. Profit is growing slower than sales: rising costs are taking part of the growth.

Shree Ganesh Remedies Ltd reported ₹23.3 Cr of revenue in the Sep 2026 quarter, −23.2% on the same quarter a year earlier. Over 10 years it has grown 21.2% a year on average. The last full year, FY26, came in at ₹109 Cr. The last four reported quarters add to ₹92.0 Cr.

Revenue is everything the company billed its customers in the period.

FY26 revenue was ₹109 Cr, +0.0% on the year before.

Recent pace: the last four quarters grew −12.8% on average, against 21.2% a year over the longer run, so this year is growing slower than its own long-run rate.

Is growth speeding up? Revenue over the last 12 months grew −13.6%, against −13.3% a year over the last 8 quarters (stabilising); profit over the last 12 months grew −40.7%, against −34.8% a year (rolling over).

Shree Ganesh Remedies Ltd's operating margin was 16.9% in the Sep 2026 quarter, 14.8 percentage points lower than the same quarter a year ago. Across 13 years it has been between 12.0% and 36.0%. The latest quarter is within that range.

Operating margin is what is left from every ₹100 of sales after the costs of running the business, before interest and tax. It shows pricing power and cost control.

Why the margin moved: operating margin changed −14.8 percentage points on the year while gross margin changed +0.7 points. So the drop came mostly from costs below the gross margin, such as staff and overheads, measured against sales.

Over the last 3 years, 123% of Shree Ganesh Remedies Ltd's reported profit came in as cash from its operations, so the profit is backed by cash. In FY26 it brought in ₹24.0 Cr of operating cash against ₹18.0 Cr of profit. After ₹24.0 Cr of spending on assets, ₹0.0 Cr was left over as free cash.

The profit and loss account shows what was earned. The cash-flow statement shows the cash that actually came in. Comparing operating cash flow with profit is one of the best checks that a profit is real.

Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year.

Why 123% of profit came in as cash: the cash cycle got 31 days longer between FY21 and FY26, so more of each rupee of profit waits in the business before it arrives.

What to look at next: the bigger use of cash is spending on new assets, at 2.7× depreciation over three years. The next section checks what that spending is building.

Shree Ganesh Remedies Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 236 days in FY26, up from 205 days in FY21. It spent ₹71.0 Cr on assets over the last 3 years. Customers take 109 days to pay, and stock sits for 209 days on average.

Working capital is the cash tied up between paying suppliers and getting paid. Debtor days: how long customers take to pay. Inventory days: how long stock sits. The cash cycle: the whole loop, in days of sales.

At FY26 sales of ₹109 Cr, each day of that cycle ties up about ₹0.3 Cr, so roughly ₹70.0 Cr is tied up in the business at any time.

FY26: customers took 109 days to pay and stock sat for 209 days, about 6.9 months of sales sitting as stock, for a full cycle of 236 days, longer than FY21's 205.

The full loop: cash goes out to suppliers and production on day 0. Stock sits for 209 days. Customers pay about 109 days after that. Suppliers are paid at 82 days. Together that makes the 236-day cycle.

Spending on assets: ₹71.0 Cr over the last 3 years, against ₹26.0 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹13.0 Cr (FY26): assets paid for that are not earning yet.

In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns.

Shree Ganesh Remedies Ltd's P/E is 69.1×, near the high end of its own history: higher than 91% of past readings. Its usual P/E (the middle reading) is 35.5×, over 6.2 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth.

P/E is the share price divided by a year's profit per share: how many rupees the market pays for each rupee of yearly profit.

Why the multiple is where it is: over the past year earnings per share moved −23.0% while the price moved +33.3%. The price did better than earnings, which pushed the multiple up within its own range.

Where the price move came from: over 5 years the price moved +11.9% a year; about +9.6% a year came from earnings growth and about +2.3 percentage points from the multiple (the market paying more). The split is approximate (price return minus earnings growth). It shows how much of the move came from the market paying a different multiple.

In short: the multiple is high against its own past, so the earnings trend underneath matters more than the multiple.

Shree Ganesh Remedies Ltd's business is getting worse. Revenue, profit and EPS growth are shrinking: revenue growth is −13.6% in the latest quarter, against +61.9% at its best in 12 quarters, with ROCE falling at 13.2%. This is based on 12 quarters of 4 measures.

Every business is somewhere on a path of getting better or worse, and this section names where. The last 12 quarters of growth in revenue, profit and earnings per share, plus the return the business earns on its capital, are read as lines. Getting worse: the lines are falling. Turning around: a low point has just formed and the last few quarters are rising from it. Getting better: the rise from the low has lasted. Growing steadily: steady growth with healthy returns. Slowing from a peak: still high, but slowing. When the lines disagree the result is mixed; too little history means no reading. CAGR (compound annual growth rate) is the steady yearly rate that would turn the starting value into the latest one. It is the fairest way to compare growth over different periods. If the 1-year figure is much bigger than the 10-year one, recent growth is running faster than the long-run trend. A dash means there is no figure for that period, or the starting year was a loss, where a growth rate means nothing.

Why it matters: falling lines mean any ratio below that looks low should be read with that direction in mind.

Compound annual growth rate (%)

Compound annual growth rate over each period, %. Revenue, profit and EPS come from yearly figures; the share price row is price growth over the same periods. A dash means no figure for that period, or the starting year was a loss.

Shree Ganesh Remedies Ltd earned a ROCE of 14% in FY26. That is up from a low of 12% in FY16. Its return on capital used (ROIC) is 4.3 percentage points below its cost of capital, so growth here does not yet pay for the capital it uses.

Return on capital employed (ROCE) is the profit the whole business earns on all the money in it, from shareholders and lenders together. It is the best single test of whether growth adds value or just size.

It comes from a 16.5% net margin and 0.52× asset turnover (sales divided by assets).

Why the return is what it is (FY26): a 16.5% net margin × 0.52× asset turnover × 1.28× leverage (assets divided by equity) ≈ 11.0% on equity. The margin does most of the work; borrowing plays a small part, so this return is earned, not borrowed.

The key test, return on capital used minus the cost of capital: 7.7% − 12.0% = −4.3 percentage points. The 12.0% is a standard assumption for the cost of capital in India, not an estimate for this company. Read the sign and size of the gap, not the decimals. Negative: growth at these returns loses value until returns improve.

The 7.7% ROIC above is the latest reading, as reported. The yearly chart below shows FY26 at 11.8%, and the quarterly chart works out each 12-month window from the quarterly figures, so the readings differ by date, not by method.